A best evidence topic was written according to a structured protocol. The question addressed was whether silver nitrate (SN) is an effective means of pleurodesis. A total of 42 papers were identified using the reported search, of which 8 represented the best evidence to address the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Three studies assessed the efficacy of SN in inducing pleurodesis in patients with malignant pleural effusion (MPE). Using intrapleural injections of SN in concentrations of 0.5-1%, they reported success rates of 89-96% at 30 days. One of these studies compared SN with talc slurry and found equally effective pleurodesis at monthly intervals up to 4 months (P = 0.349-1). Another two studies retrospectively reviewed the efficacy of thoracosopic SN instillation (1 or 10%) in patients with primary spontaneous pneumothorax (PSP). Recurrence rates were 0-1.1% during long-term follow-up. One of these compared SN with simple drainage and reported a therapeutic gain of 45 ± 30% (95% CI) with SN, at the cost of increased analgesia consumption, chest drainage and hospital stay. Finally, three studies reported the results of the comparison of intrapleural injections of SN, talc or tetracycline in inducing pleurodesis in rabbits. SN was equally effective with tetracycline and superior to talc at producing pleurodesis, with lower concentrations of SN (0.1%) resulting in significantly attenuated systemic inflammatory response when compared with either higher SN concentrations (0.5%) or talc. Although not commonly used, available evidence suggests that SN is an effective agent in inducing pleurodesis in patients with either MPE or PSP. Compared with universally employed talc, it seems to result in at least similar short-term recurrence rates for MPE, with a demonstrably good side-effect profile; the longer-term efficacy is, as yet, undetermined. In cases of PSP, evidence suggests that thoracoscopic SN instillation is at least as effective as talc, with potentially fewer systemic side effects.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In patients undergoing [surgery to achieve pleurodesis], does [silver nitrate produce an effective pleurodesis], with lower rates of recurrence and fewer complications when [compared with current management strategies]?
CLINICAL SCENARIO
You are seeing a new patient in clinic, referred for recurrent pneumothoraces. You feel that she would benefit from a video-assisted thoracoscopic surgery (VATS) procedure with talc pleurodesis and start to discuss this management strategy with her. The patient says that she knew somebody who had a similar thing, but that 'silver' was used to keep the lung up. The patient has read up on the subject, and wonders whether silver nitrate (SN) has any advantages over current methods for pleurodesis. You are not sure and resolve to review the literature on the topic yourself.
SEARCH STRATEGY
A systematic search of Medline (R) from 1946 to December 2014 using the Ovid interface. The search strategy employed: [(exp Pleurodesis/) OR (exp Pleural Effusion/) OR (exp Pneumothorax/)] AND (exp Silver Nitrate/). 
The use of SN for pleurodesis in unilateral MPE is at least as effective as talc slurry, with no significant difference in adverse effects or pain scores
Study limitations: 11 of the original 60 patients were lost to follow-up, the study was underpowered (power = 0.065) and investigators were not blinded to the treatment 
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RESULTS
Menna et al. [2] found that SN slurry was an effective agent for inducing pleurodesis after unsuccessful talc poudrage for unilateral malignant pleural effusion (MPE). In their cohort of 17 patients, 15 of them (89%) had successful pleurodesis at 30 days with intrapleural injections of SN 1%. Although 5 patients developed a postprocedural fever, there were no serious untoward side effects.
In a larger study of 70 hemithoraces (63 patients), Terra et al.
[3] also demonstrated that SN slurry was effective at inducing pleurodesis in cases of MPE. SN 0.5% was used in the outpatient setting and at the 30-day follow-up 45 patients were re-evaluated (48 hemithoraces), with 46 of them (95.8%) showing successful pleurodesis. There were few complications and, although 10% of patients reported pain after the procedure in the immediate short term, follow-up revealed a significant improvement in both the physical and environmental aspects of quality of life (P < 0.05).
Paschoalini et al. [4] randomized 60 patients with unilateral MPE to receive an intrapleural injection of either SN 0.5% (SN group, n = 33) or talc slurry (talc group, n = 27) for pleurodesis. The use of SN for pleurodesis was at least as effective as talc slurry, with success rates of 96 and 84%, respectively (P = 0.35) at 30 days. There were no significant differences in adverse effects, chest drain output, hospital stay or pain scores.
Exploring other patient groups, Marcheix et al. [5] looked at the results of a series of 603 patients treated with VATS SN 1% pleurodesis for primary spontaneous pneumothorax (PSP). They found a recurrence rate of only 0.5% at 30 days, with no deaths or serious untoward effects. Long-term follow-up of 184 patients (2.9 ± 2.3 years) demonstrated a very low recurrence rate of 1.1%.
Wied et al. [6] performed a study in which 27 patients with PSP were randomized to receive thoracoscopic SN 10% pleurodesis (N = 16, 59%) or simple drainage (N = 11, 41%). SN pleurodesis resulted in significantly fewer recurrences when compared with simple drainage (0 vs 5, respectively) during follow-up (5-19 months). Analgesia use, chest drainage and hospital stay were increased in patients undergoing SN pleurodesis compared with those undergoing simple drainage (median of 8 vs 5 days, respectively), but when recurrence occurred in the latter group, hospital stay was increased by 4-40 days (median 11 days).
There are also three important animal studies to consider. The study by Vargas et al. [7] randomized 140 rabbits into two groups, receiving intrapleural injections of either 0.5% SN (SN group, n = 70) or 400 g/kg talc slurry (talc group, n = 70). Both gross and microscopic pleurodesis scores (Table 1) were assessed at regular intervals up to 12 months. The results showed that 0.5% SN is more effective than talc 400 mg/kg in inducing pleurodesis in rabbits: at all time points, the mean pleurodesis score was at the effective level (>3) for SN and ineffective level (<3) for talc (P < 0.001). Of note, three subjects developed a haemothorax in the SN group, whereas no subjects in the talc group developed this complication. There was no other morbidity incurred in either group.
In another study by Vargas et al. [8] , three groups of 10 rabbits received intrapleural injections of 0.25% SN, 0.5% SN or tetracycline (35 mg/kg). The authors reviewed both gross and microscopic pleurodesis at 28 days. It was found that 0.5% SN was as effective at producing pleurodesis as tetracycline at 25 mg/kg in their rabbit model, with a superior side-effect profile, as 10-20% developed haemothorax, compared with 50% in the tetracycline group. The clinical significance of the haemothorax in these two studies is unclear, but it is notable that it occurred only in the animal studies. Finally, another study was reported by Marchi and colleagues [9] , where 78 rabbits received intrapleural injections of 0.1% SN, 0.5% SN or 100 or 400 mg/kg talc. Using various biochemical markers (leucocytes, neutrophils, lactate dehydrogenase, IL-8 and vascular endothelial growth factor), local and systemic inflammatory responses were evaluated. Intrapleural injection of 0.1% SN induced intense pleural inflammation, but with a much attenuated systemic response when compared with 0.5% SN or talc. The study did not look directly at pleurodesis and is, therefore, not included in the table, but provides important information on the potential lack of systemic side effects of SN.
CLINICAL BOTTOMLINE
Evidence suggests that SN is an effective agent in inducing pleurodesis in patients with either MPE or PSP. Compared with universally employed talc, SN seems to result in at least similar recurrence rates in the short term for MPE, with a demonstrably good side-effect profile. Although the longer-term efficacy of SN is, as yet, undetermined, it may also be useful in cases of MPE where talc poudrage has failed. In cases of PSP, evidence suggests that thoracoscopic SN instillation is at least as effective as talc, with potentially fewer systemic side effects.
